CAJ | 학술논문

目的：探讨细胞外基质金属蛋白酶诱导分子（EMMPRIN）在胰腺肿瘤组织、血清以及肿瘤微环境中的表达及临床意义。方法应用QRT-PCR、免疫组化以及ELISA方法检测50例胰腺导管细胞癌（PDCA）、20例导管内乳头状黏液腺瘤（IPMN）、10例浆液性囊腺瘤（SCN）、10例黏液性囊腺瘤（MCN）、10例胰腺神经内分泌瘤（NET）患者肿瘤组织、10例健康对照组胰腺组织及血清中EMMPRIN的表达，分析EMMPRIN表达与患者性别、年龄、组织学分化程度、肿瘤神经浸润、淋巴结转移、临床分期的关系。结果胰腺各组肿瘤组织中EMMPRIN mRNA水平明显增高，即PDCA[（4148.14±1825.36）copies/μl，P=0.000]、NET[（4654.23±2168.48）copies/μl，P=0.000]、IPMN[（3332.54±1837.47）copies/μl，P=0.000]、SCN[（3328.66±1618.36）copies/μl，P=0.000]及MCN[（2275.27±1019.40）copies/μl，P=0.000]是正常胰腺组织[（649.90±408.22）copies/μl]的4.3～7.2倍，差异有统计学意义；在标本血清中EMMPRIN蛋白在PDCA[（5.53±4.14）ng/100μl， P=0.000]、IPMN[（3.28±2.77）ng/100μl，P=0.001]、NET[（5.48±4.21）ng/100μl，P=0.002]、SCN[（1.13±0.49）ng/100μl，P=0.007]、MCN[（2.77±4.24）ng/100μl，P=0.000]的表达均明显高于正常对照组[（0.63±0.18）ng/100μl]，差异有统计学意义。EMMPRIN在肿瘤组织及血清中的表达与胰腺导管细胞癌的分期有关（χ2组织=0.278，P=0.041；χ2血清=0.424，P=0.001），伴有神经浸润患者较无神经浸润患者血清中EMMPRIN表达增加（χ2血清=4.728，P=0.03），EMMPRIN表达与患者的年龄、性别、肿瘤部位、肿瘤大小及淋巴结转移无明显相关。结论 EMMPRIN在各种胰腺肿瘤组织及血清中高表达，可能与其恶性程度相关。
목적：탐토세포외기질금속단백매유도분자（EMMPRIN）재이선종류조직、혈청이급종류미배경중적표체급림상의의。방법응용QRT-PCR、면역조화이급ELISA방법검측50례이선도관세포암（PDCA）、20례도관내유두상점액선류（IPMN）、10례장액성낭선류（SCN）、10례점액성낭선류（MCN）、10례이선신경내분비류（NET）환자종류조직、10례건강대조조이선조직급혈청중EMMPRIN적표체，분석EMMPRIN표체여환자성별、년령、조직학분화정도、종류신경침윤、림파결전이、림상분기적관계。결과이선각조종류조직중EMMPRIN mRNA수평명현증고，즉PDCA[（4148.14±1825.36）copies/μl，P=0.000]、NET[（4654.23±2168.48）copies/μl，P=0.000]、IPMN[（3332.54±1837.47）copies/μl，P=0.000]、SCN[（3328.66±1618.36）copies/μl，P=0.000]급MCN[（2275.27±1019.40）copies/μl，P=0.000]시정상이선조직[（649.90±408.22）copies/μl]적4.3～7.2배，차이유통계학의의；재표본혈청중EMMPRIN단백재PDCA[（5.53±4.14）ng/100μl， P=0.000]、IPMN[（3.28±2.77）ng/100μl，P=0.001]、NET[（5.48±4.21）ng/100μl，P=0.002]、SCN[（1.13±0.49）ng/100μl，P=0.007]、MCN[（2.77±4.24）ng/100μl，P=0.000]적표체균명현고우정상대조조[（0.63±0.18）ng/100μl]，차이유통계학의의。EMMPRIN재종류조직급혈청중적표체여이선도관세포암적분기유관（χ2조직=0.278，P=0.041；χ2혈청=0.424，P=0.001），반유신경침윤환자교무신경침윤환자혈청중EMMPRIN표체증가（χ2혈청=4.728，P=0.03），EMMPRIN표체여환자적년령、성별、종류부위、종류대소급림파결전이무명현상관。결론 EMMPRIN재각충이선종류조직급혈청중고표체，가능여기악성정도상관。
Objective To study the expression and clinical significance of extracellular matrix metalloproteinase inducer (EMMPRIN) in pancreatic neoplasm's tissues, sera, as well as in tumor microenvironment. Methods Methods of QRT-PCR, immunohistochemistry and ELISA were applied to test the expression of EMMPRIN in both tissues and sera in 50 cases of pancreatic ductal cell carcinoma (PDCA), 20 cases of intraductal papillary mucinous neoplasm (IPMN), 10 cases of serous cystic neoplasm (SCN), 10 cases of mucinous cystic neoplasm (MCN), 10 cases of pancreatic neuroendocrine tumor (NET) as well as 10 cases of healthy control (N), and to analyze the relationship between EMMPRIN expression and patients' gender, age, histologic differentiation, lymph node metastasis, clinical stage. Results EMMPRIN mRNA levels was significantly higher in each group of pancreatic neoplasm tissues, PDCA (4 148.14± 1 825.36) copies/μl, NET (4 654.23±2 168.48) copies/μl, IPMN (3 332.54±1 837.47) copies/μl, SCN (3 328.66±1 618.36) copies/μl, and MCN (2 275.27±1 019.40) copies/μl, ranging from 4.3 to 7.2 times of the healthy control group (649.90±408.22) copies/μl (P=0.000); EMMPRIN protein was statistically highly expressed in the sera of PDCA (5.53±4.14) ng/100 μl (P=0.000), IPMN (3.28±2.77) ng/100 μl (P=0.001), NET (5.48±4.21) ng/100 μl (P=0.002), SCN (1.13±0.49) ng/100 μl (P=0.007), MCN (2.77±4.24) ng/100μl(P=0.000) compared with the healthy control group (0.63±0.18) ng/100 μl; There was a positive correlation of EMMPRIN expression in tissues and sera between PDCA and tumor stages (χ2tissue=0.278, P=0.041; χ2sera=0.424, P=0.001). Patients with perineural invasion secreted more EMMPRIN in sera than those without perineural invasion (χ2sera=4.728, P=0.03), and there seemed no relationship between EMMRIN expression and patient's age, sex, tumor location, tumor size and lymph node metastasis. Conclusion EMMPRIN was highly expressed in a variety of pancreatic neoplasm tissues and sera, which may be associated with the progression of malignancy.